Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Dow
Queensland Health
Deloitte
McKesson
Johnson and Johnson
Daiichi Sankyo
Federal Trade Commission
Fuji
QuintilesIMS
Novartis

Generated: August 18, 2017

DrugPatentWatch Database Preview

Horizon Theraps Inc Company Profile

« Back to Dashboard

What is the competitive landscape for HORIZON THERAPS INC, and when can generic versions of HORIZON THERAPS INC drugs launch?

HORIZON THERAPS INC has one approved drug.

There are seven US patents protecting HORIZON THERAPS INC drugs.

There are fifty-four patent family members on HORIZON THERAPS INC drugs in twenty-six countries.

Summary for Applicant: Horizon Theraps Inc

Patents:7
Tradenames:1
Ingredients:1
NDAs:1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Horizon Theraps Inc
RAVICTI
glycerol phenylbutyrate
LIQUID;ORAL203284-001Feb 1, 2013RXYesYes► Subscribe► Subscribe ► Subscribe
Horizon Theraps Inc
RAVICTI
glycerol phenylbutyrate
LIQUID;ORAL203284-001Feb 1, 2013RXYesYes► Subscribe► SubscribeYY ► Subscribe
Horizon Theraps Inc
RAVICTI
glycerol phenylbutyrate
LIQUID;ORAL203284-001Feb 1, 2013RXYesYes► Subscribe► Subscribe ► Subscribe
Horizon Theraps Inc
RAVICTI
glycerol phenylbutyrate
LIQUID;ORAL203284-001Feb 1, 2013RXYesYes► Subscribe► Subscribe► Subscribe
Horizon Theraps Inc
RAVICTI
glycerol phenylbutyrate
LIQUID;ORAL203284-001Feb 1, 2013RXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for HORIZON THERAPS INC drugs

Drugname Dosage Strength Tradename Submissiondate
glycerol phenylbutyrate
Oral Liquid1.1 g/mL
RAVICTI
11/19/2013

Non-Orange Book Patents for Horizon Theraps Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,060,510 Triglycerides and ethyl esters of phenylalkanoic acid and phenylalkenoic acid useful in the treatment of various disorders► Subscribe
6,083,984 Triglycerides and ethyl esters of phenylalkanoic acid and phenylalkenoic acid useful in the treatment of various disorders► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Horizon Theraps Inc Drugs

Country Document Number Estimated Expiration
Canada2735218► Subscribe
World Intellectual Property Organization (WIPO)2009134460► Subscribe
Australia4858796► Subscribe
Japan2012501451► Subscribe
European Patent Office2846791► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Horizon Theraps Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2016 00062Denmark► SubscribePRODUCT NAME: GLYCEROLPHENYLBUTYRAT; REG. NO/DATE: EU/1/15/1062/001-004 20151201
2016000107Germany► SubscribePRODUCT NAME: GLYCEROLPHENYLBUTYRAT; REGISTRATION NO/DATE: EU/1/15/1062 20151127
0160044 00204Estonia► SubscribePRODUCT NAME: GLUETSEROOLFENUEUELBUTUERAAT;REG NO/DATE: EU/1/15/1062 01.12.2015
2016 00062Denmark► SubscribePRODUCT NAME: GLYCEROLPHENYLBUTYRAT; REG. NO/DATE: EU/1/15/1062/001-004 20151201
2016041Lithuania► SubscribePRODUCT NAME: GLICEROLIO FENILBUTIRATAS; REGISTRATION NO/DATE: EU/1/15/1062 20151127
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

McKesson
Citi
Covington
Express Scripts
Deloitte
Dow
QuintilesIMS
Baxter
Chubb
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot